The Iolyx Pipeline

Iolyx is focused on treating autoimmune or inflammation-driven ophthalmologic diseases at the source of their inflammation. Trials for ILYX-002 are underway, followed by a pipeline of therapeutics in development.

Our continued work across the front and back of eye is designed to test the safety and efficacy of our products – ensuring that they are transformative to the standard of care in immuno-ophthalmology.